The antimicrobial spectrum and pharmacokinetic properties of moxalactam suggest that it should be a useful agent for the empirical treatment of urinary tract infections in patients with normal renal function (2, 4-6, 8-15, 17-20) . In this prospective randomized study of patients with acute urinary tract infections, the efficacy of this new antibiotic was compared with that of cefazolin, an agent of proven usefulness in this clinical setting (3, 7) . Patients were evaluated for clinical and bacteriological response, duration of hospital stay, and adverse drug reactions.
MATERIALS AND METHODS
The patients in this study were A laboratory profile (hematocrit, hemoglobin, leukocyte count, blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, total bilirubin, and urinalysis), blood culture, and clean-catch midstream or catheterized urine for quantitative culture and susceptibility were obtained before the institution of therapy. Coagulation studies were not obtained routinely during the course of this investigation.
Significant numbers (>10' colony-forming units per ml) of a sensitive bacterial pathogen had to be isolated from the admission urine sample. Organisms isolated from urine and blood were identified with an Analytical Profile Index 20E (Analytab Products, Plainview, N.Y.). Kirby-Bauer susceptibility testing was performed on Mueller-Hinton agar with a standard cephalothin disk and a 30-,Lg moxalactam disk (1).
Antibiotic therapy was continued for a minimum of 5 days and until the patient had remained afebrile for 72 h. The laboratory profile and urine culture were repeated on hospital day 3 and again at the end of therapy. Follow-up clean-catch midstream urine samples for culture and susceptibility were obtained between 5 and 10 days after discharge. A laboratory profile was obtained at that time only if hematological or chemical abnormalities attributable to antibiotic therapy had occurred during the treatment period.
The therapeutic effects of both agents were assessed on the basis of the sequential urine cultures obtained from each patient. The criteria were as follows: cure, absence of significant bacteriuria at follow-up; recurrence, significant bacteriuria with the initial organism at follow-up; reinfection, significant bacteriuria with a different organism at follow-up; and superinfection, significant bacteriuria with a different organism while undergoing therapy.
Results were compared by using the chi-square test for discreet variables and Student's t test for continuous variables. A P value of less than 0.05 was considered significant. Fifty-five patients with no known predisposing condition for a urinary tract infection (uncomplicated patients) participated in this study. Of these, 29 received moxalactam and 26 received cefazolin. The length of hospital stay was similar for moxalactam-treated (5.6 days) and cefazolin-treated (5.5 days) patients. The causative bacterial pathogen had been eliminated from the urine of all these patients by the time of discharge. A total of 22 of the moxalactamtreated patients and 20 of the cefazolin-treated patients returned for follow-up urine cultures 5 to 10 days after the cessation of therapy (Table  1) . Of the moxalactam group, two (9.1%) patients had recurrent infections and two (9.1%) had reinfections. One of the reinfections was due to a different organism, and the other was due to E. coli with a different susceptibility pattern. In the cefazolin group, two (10%) patients had recurrent infections and none had a reinfection. The difference in the recurrence rates between the two groups was not statistically significant.
RESULTS

Eighty
Twenty-seven patients in this study had an underlying condition predisposing them to urinary tract infections (complicated patients). Of these, 12 belonged to the moxalactam group and 15 belonged to the cefazolin group. The length of hospital stay was 5.7 days for both groups of patients. The causative bacterial pathogen had been eliminated from the urine of all these patients by the time of discharge. Seven moxalactam patients and 12 cefazolin patients returned for follow-up culture 5 to 10 days after the cessation of therapy (Table 1) . Three (43%) moxalactam-treated patients and five (42%) cefazolin-treated patients had recurrent infections. The difference in the recurrence rates between these two groups of patients was not statistically significant. There were no reinfections in either group.
During the course of this study, six patients developed significant bacteriuria with another organism while undergoing therapy (Table 1) . Five (12.2%) patients in the moxalactam group developed superinfections with Streptococcus faecalis. This phenomenon was observed in 25% of the complicated patients and 6.9% of the uncomplicated patients in this group. None of these patients were symptomatic and in two cases the organism spontaneously disappeared patients treated with moxalactam and 16 (39%o) patients treated with cefazolin (P = not significant). The elevation of one or more hepatic enzymes (serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, and alkaline phosphatase) to an abnormal level (at. least twice the level at admission) occurred in 15 (36.5%) patients treated with moxalactam and 6 (14.6%) patients -treated with cefazolin. This difference was statistically significant. There was no difference between the two groups when the incidence of leukopenia (fewer than 4,000 leukocytes per mm3), eosinophilia (greater than 5%), thrombophlebitis, and pruritis was compared ( 
